You are on page 1of 1

Federal Register / Vol. 70, No.

130 / Friday, July 8, 2005 / Notices 39525

Name of Committee: Center for Scientific referenced at HHS as E–276–2004/0– Dated: June 30, 2005.
Review Special Emphasis Panel, Sensory US–01 and E–276–2004/0–US–01 Steven M. Ferguson,
SBIRs. respectively to Biosite, Inc., having a Director, Division of Technology Development
Date: July 27, 2005. place of business in the state of and Transfer, Office of Technology Transfer,
Time: 1 p.m. to 3 p.m. National Institutes of Health.
Agenda: To review and evaluate grant
California. The field of use may be
applications. limited to an FDA approved clinical [FR Doc. 05–13460 Filed 7–7–05; 8:45 am]
Place: National Institutes of Health, 6701 diagnostic product for atherosclerosis. BILLING CODE 4140–01–P
Rockledge Drive, Bethesda, MD 20892, The United States of America is the
(Telephone Conference Call). assignee of the patent rights in this
Contact Person: Bernard F. Driscoll, PhD, invention. The territory may be DEPARTMENT OF HEALTH AND
Scientific Review Administrator, Center for worldwide. This announcement is the HUMAN SERVICES
Scientific Review, National Institutes of first notice to grant an exclusive license
Health, 6701 Rockledge Drive, Room 5184, to this technology. National Institutes of Health
MSC 7844, Bethesda, MD 20892, (301) 435–
1242, driscolb@csr.nih.gov. DATES: Only written comments and/or Prospective Grant of Exclusive
Name of Committee: Center for Scientific application for a license, which are License: Heat Induced Gene
Review Special Emphasis Panel, received by the NIH Office of Expression to Treat Cancer
Chemoprevention of Lung Cancer. Technology Transfer on or before
Date: July 29, 2005. AGENCY: National Institutes of Health,
September 6, 2005 will be considered. Public Health Service, HHS.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant ADDRESSES: Requests for a copy of the ACTION: Notice.
applications. patent applications, inquiries,
Place: National Institutes of Health, 6701 comments and other materials relating SUMMARY: This is notice, in accordance
Rockledge Drive, Bethesda, MD 20892, to the contemplated license should be with 35 U.S.C. 209(c)(1) and 37 CFR
(Telephone Conference Call). directed to: Fatima Sayyid, Technology part 404.7(a)(1)(i), that the National
Contact Person: Eun Ah Cho, PhD, Institutes of Health, Department of
Scientific Review Administrator, Center for
Licensing Specialist, Office of
Technology Transfer, National Institutes Health and Human Services, is
Scientific Review, National Institutes of contemplating the grant of an exclusive
Health, 6701 Rockledge Drive, Room 6202, of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804; patent license to practice the inventions
MSC 7804, Bethesda, MD 20892, (301) 451–
Telephone: (301) 435–4521; Facsimile: embodied in U.S. Provisional Patent
4467, choe@csr.nih.gov.
(301) 402–0220; e-mail: Application Serial No. 60/024,213,
(Catalogue of Federal Domestic Assistance entitled ‘‘Spatially And Temporal
Program Nos. 93.306, Comparative Medicine; sayyidf@mail.nih.gov.
Control Of Gene Expression Using A
93.333, Clinical Research, 93.306, 93.333,
SUPPLEMENTARY INFORMATION: The Heat Shock Protein Promoter In
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National subject provisional patent applications Combination With Local Heat’’ filed
Institutes of Health, HHS) are related to the field of vascular August 15, 1996 (E–235–1995/0–US–
disease and markers expressed in 01), and all related foreign patents/
Dated: June 29, 2005.
peripheral blood or secreted into serum. patent applications, to New England
LaVerne Y. Stringfield, OncoTherapeutics, Inc., having a place
Specifically, the claims are directed to
Director, Office of Federal Advisory a method of diagnosing atherosclerosis of business in Cambridge,
Committee Policy. Massachusetts. The patent rights in
or determining the progression of
[FR Doc. 05–13464 Filed 7–7–05; 8:45 am] atherosclerosis in a subject by assaying these inventions have been assigned to
BILLING CODE 4140–01–M the expression of FOS, DUSP1, or both the United States of America.
FOS and DUSP1 in monocytes from the The prospective exclusive license
subject wherein an increased expression territory may be worldwide and the
DEPARTMENT OF HEALTH AND of either or both markers indicates field of use may be limited to gene-
HUMAN SERVICES atherosclerosis or severity of based therapeutics which incorporate
atherosclerosis in a subject. focused ultrasound heating technologies
National Institutes of Health to treat cancer.
The prospective exclusive license will
Prospective Grant of Exclusive be royalty-bearing and will comply with DATES: Only written comments and/or
License: Method for Diagnosis of the terms and conditions of 35 U.S.C. license applications that are received by
Atherosclerosis 209 and 37 CFR 404.7. The prospective the National Institutes of Health on or
exclusive license may be granted unless, before September 6, 2005 will be
AGENCY: National Institutes of Health, considered.
within 60 days from the date of this
Public Health Service, HHS.
published Notice, NIH receives written ADDRESSES: Requests for copies of the
ACTION: Notice. patent, inquiries, comments and other
evidence and argument that establishes
SUMMARY: This is notice, in accordance that the grant of the license would not materials relating to the contemplated
with 35 U.S.C. 209(c)(1) and 37 CFR be consistent with the requirements of exclusive license should be directed to:
404.7(a)(1)(i), that the National 35 U.S.C. 209 and 37 CFR 404.7. George G. Pipia, Ph.D., Technology
Institutes of Health (NIH), Department Properly filed competing applications Licensing Specialist, Office of
of Health and Human Services (HHS), is for a license filed in response to this Technology Transfer, National Institutes
contemplating the grant of an exclusive notice will be treated as objections to of Health, 6011 Executive Boulevard,
license worldwide to practice the the contemplated license. Comments Suite 325, Rockville, MD 20852–3804;
invention embodied in: Provisional and objections submitted in response to Telephone: (301) 435–5560; Facsimile:
Patent Application Serial No. 60/ this notice will not be made available (301) 402–0220; E-mail:
607,031 filed 9/3/2004, and Provisional for public inspection, and, to the extent pipiag@mail.nih.gov.
Patent Application Serial No. 60/ permitted by law, will not be released SUPPLEMENTARY INFORMATION: The
618,275 filed 10/12/2004 titled ‘‘Method under the Freedom of Information Act, above-mentioned patent application
for Diagnosis of Atherosclerosis’’ 5 U.S.C. 552. describes methods of using heat to

VerDate jul<14>2003 16:32 Jul 07, 2005 Jkt 205001 PO 00000 Frm 00043 Fmt 4703 Sfmt 4703 E:\FR\FM\08JYN1.SGM 08JYN1